Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis

Article Medicine, General & Internal

Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States A Cost-Effectiveness Analysis

Anne M. Neilan et al.

Summary: The study found that although CAB-LA offers more benefits over F/TDF, effective oral PrEP limits the additional price society should be willing to pay for CAB-LA.

ANNALS OF INTERNAL MEDICINE (2022)

Add to Collection

Article Infectious Diseases

Past dynamics of HIV transmission among men who have sex with men in Montreal, Canada: a mathematical modeling study

Rachael M. Milwid et al.

Summary: This study estimated the evolving role of prevention and sexual behavior on HIV transmission among gbMSM in Montreal. The findings showed a significant decline in HIV incidence and identified age, sexual partnering level, and gaps in the HIV care continuum as important factors contributing to HIV transmission.

BMC INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

Sinead Delany-Moretlwe et al.

Summary: The study aimed to assess the safety and efficacy of injectable cabotegravir compared with daily oral tenofovir diphosphate plus emtricitabine for HIV prevention in HIV-uninfected women. The results showed that cabotegravir was superior to TDF-FTC in preventing HIV infection among women.

LANCET (2022)

Add to Collection

Article Immunology

Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?

Heather-Marie A Schmidt et al.

Lancet HIV (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study

Hugo Jourdain et al.

Lancet Public Health (2022)

Add to Collection

Article Immunology

Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012-2017

Ya-Lin A. Huang et al.

Summary: Commercially insured individuals with PrEP persisted for a longer median time of 13.7 months compared to Medicaid insured patients with 6.8 months. Factors like female sex, younger age, residence in rural location, and black race were associated with shorter persistence.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model

Kevin M. Maloney et al.

Summary: The study found that if 50% of people chose LAI-PrEP, 4.3% of infections could be averted over 10 years. LAI-PrEP is expected to have a slightly greater impact than the DO-PrEP-only regimen, especially with assumptions of higher adherence and partial protection after discontinuation. If the total PrEP initiation rate doubled, 17.1% of infections would be averted, pointing to the potential for increased population-level impact with higher PrEP coverage.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Raphael J. Landovitz et al.

Summary: The study showed that injectable Cabotegravir was more effective in preventing HIV infection among MSM and transgender women compared to daily oral Tenofovir Disoproxil Fumarate-Emtricitabine. Strategies are needed to prevent INSTI resistance in cases of Cabotegravir PrEP failure.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health